Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy.
The effects of dietary protein and converting enzyme inhibition (CEI) on chronic puromycin aminonucleoside nephropathy (PAN) were studied. PAN was induced with seven SQ injections of puromycin aminonucleoside 20 mg/kg over 10 weeks in male Sprague-Dawley rats. The rats were divided into a 22.5% protein diet group (Gr 1), a 6% protein diet group (Gr 2), and an enalapril-treated group on 22.5% protein diet (Gr 3). Group 4 animals served as age-matched controls. Both diets were isocaloric and had the same phosphorus content. Rats from groups 1, 2, and 4 were sacrificed at 12, 18 and 24 weeks. Five rats of group 3 were sacrificed at 12 weeks, and the others were divided in subgroups 3A (diet changed to 6% protein) and 3B (no changes); half of each subgroup was sacrificed at 18 and 24 weeks, respectively. Group 2 had significantly less proteinuria than group 1 at all times. Group 3 had the same proteinuria as group 1 until 12 weeks and then began to decrease. In group 3A proteinuria decreased to group 2 levels, while in group 3B the decrease was slower but still prominent. Early lesions of focal and segmental glomerular sclerosis/hyalinosis (FSH) were present in groups 1, 2, 3 at 12 weeks (16 +/- 1.2%, 15 +/- 1.3%, 7 +/- 1.3%, respectively, versus 1.3 +/- 0.4% in controls), but by 18 weeks a reversal in FSH was seen in groups 2 and 3A/B (3 +/- 1.6%, 2 +/- 0.4%, and 3 +/- 0.9%, respectively, vs. 14 +/- 1.5% in group 1).(ABSTRACT TRUNCATED AT 250 WORDS)
Marinides
G N
GN
Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City.
Groggel
G C
GC
Cohen
A H
AH
Border
W A
WA
D000818:Animals; D004044:Dietary Proteins / Q000008:administration & dosage / Q000494:pharmacology*; D004656:Enalapril / Q000494:pharmacology* / Q000627:therapeutic use; D005923:Glomerulosclerosis, Focal Segmental / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D007668:Kidney / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008854:Microscopy, Electron; D011691:Puromycin / Q000031:analogs & derivatives; D011692:Puromycin Aminonucleoside; D051381:Rats; D011919:Rats, Inbred Strains
D004044:Dietary Proteins; D011691:Puromycin; D011692:Puromycin Aminonucleoside; D004656:Enalapril